⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
prnewswire.com
MRK
LLY
RIGL
AZN
GILD
ABBV
PFE
TMO
BMY
NVS
BIIB
Next Generation Drug Conjugates Market Trends and Global Forecasts, 2025-2035 - Lutathera, Pluvicto, Givlaari, Oxlumo, Leqvio, and Amvuttra Represent Milestones in Advanced Treatment Solutions - ResearchAndMarkets.com
businesswire.com
NVS
ALNY
ARWR
GERN
IONS
CD137 Targeted Therapy Research Report 2026-2030: 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global & Regional Clinical & Commercial Trends,
globenewswire.com
GILD
BMY
REGN
MRK
PFE
ABBV
BIIB
AZN
AMGN
NVS
GMAB
ABL
BNTX
Molecular Switch Targeting Therapies Market Research Report 2026: Opportunities in Targeted Drug Delivery Systems and Therapies in Oncology, Autoimmune, Inflammatory, and Neurological Disorders
globenewswire.com
MRK
BMY
AZN
PFE
NVS
LLY
GILD
JNJ
REGN
ABBV
NVO
SNY
VRTX
AMGN
BIIB
INCY
EXEL
SRPT
CRSP
EDIT
NTLA
ALNY
MRNA
BNTX
COHR
IMUX
INSM
CYTK
KODK
LULU
NVDA
GOOG
MSFT
IBM
AMAT
ILMN
ALKS
ACAD
MNKD
TEVA
BHC
XBI
IBB
XLF
XLK
XLV
JAZZ
ACGL
Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025: Market to Reach $63 Billion by 2031 - ResearchAndMarkets.com
businesswire.com
GILD
NVS
JNJ
SRPT
High Content Screening Market Research 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031
globenewswire.com
NVS
Endometriosis Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
ABBV
NBIX
JNJ
NVS
AMGN
Global Orphan Drugs Market to Surpass USD 443 Billion by 2031 Driven by Advances in Genomics and Precision Medicine
globenewswire.com
AZN
NVS
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
globenewswire.com
SNY
MRK
NVS
KOMO Biosciences Appoints Patient Advocate Tom Whitehead and Immunotherapy Pioneer Michael Kalos, Ph.D. to Advisory Board
businesswire.com
JNJ
LLY
NVS